Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897494 | 0.86 | NOS3 (0.39) | RAPGEF4ALDH1A1NOS3NOS2ACHE | |
| SCHEMBL18541832 | 0.81 | RAPGEF4 (0.50) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL1551822 | 0.80 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL28951 | 0.80 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL27949139 | 0.77 | RAPGEF4 (0.41) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL5180888 | 0.76 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL28482658 | 0.76 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL10412763 | 0.76 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4ECA1CA2 | |
| SCHEMBL4089566 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2C19 | |
| SCHEMBL16358719 | 0.75 | ALDH1A1 (0.48) | RAPGEF4ALDH1A1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151604-A2 | SYNERGISTS FOR DIMERIC PIGMENTS | CABOT CORPORATION (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3792270-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-03-17 | — | — | EP | disclosed |
| CN-103732632-B | Method for producing olefin block polymer using Group 4 transition metal complex | 住友化学株式会社 | 2017-07-07 | — | — | CN | disclosed |
| CN-103958548-A | Method for producing olefin block polymer using plurality of types of transition metal catalysts | SUMITOMO CHEMICAL CO | 2014-07-30 | — | — | CN | disclosed |
| US-20140187781-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | disclosed |
| CN-101878236-B | Ethylene-alpha-olefin copolymer and molded body | SUMITOMO CHEMICAL CO | 2014-05-07 | — | — | CN | disclosed |
| CN-103732632-A | Method for producing olefin block polymer using group 4 transition metal complex | SUMITOMO CHEMICAL CO | 2014-04-16 | — | — | CN | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8372850-B2 | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022502-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009104785-A1 | CATALYST COMPONENT FOR POLYMERIZATION OF ETHYLENE AND PROCESS FOR PRODUCING ETHYLENE POLYMER (1) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-27 | — | — | WO | disclosed |
| EP-0640080-B1 | SUBSTITUTED INDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX INC (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022502-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP4K5, MAP4K2 | RAPGEF4 772/4885ALDH1A1 3401/4885NOS3 2150/4885 |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K20, PRKDC | RAPGEF4 1312/4885ALDH1A1 3071/4885NOS3 3523/4885 |
| US-20140187781-A1 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP4K5, MAP4K2 | RAPGEF4 772/4885ALDH1A1 3401/4885NOS3 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.